Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Hua Zhong
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Hua Zhong wrote the following article about Crohn Disease.
 
+ Citations + Abstracts
1 Article Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients. 2020

Jang, Janice / Kwok, Benjamin / Zhong, Hua / Xia, Yuhe / Grucela, Alexis / Bernstein, Mitchell / Remzi, Feza / Hudesman, David / Chen, Jingjing / Axelrad, Jordan / Chang, Shannon. ·Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. · Department of Internal Medicine, New York University Langone Health, New York, NY, USA. · Department of Population Health, New York University Langone Health, New York, NY, USA. · Department of Surgery, New York University Langone Health, New York, NY, USA. · Department of Internal Medicine, Stanford University Medical Center, Stanford, CA, USA. · Division of Gastroenterology and Hepatology, New York University Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA. Shannon.Chang@nyulangone.org. ·Dig Dis Sci · Pubmed #31522323.

ABSTRACT: BACKGROUND: Postoperative ileus (POI) is a temporary delay of coordinated intestinal peristalsis. Alvimopan, an oral peripherally acting mu-opioid receptor antagonist approved for accelerating gastrointestinal recovery, has never been studied specifically in patients with inflammatory bowel disease (IBD). AIM: To investigate the efficacy of alvimopan in preventing POI among IBD patients. METHODS: A retrospective chart review was conducted on 246 IBD patients undergoing bowel surgery between 2012 and 2017. Data collected included demographics, IBD subtype, length of stay (LOS), postoperative gastrointestinal symptoms, and administration of alvimopan. The primary outcome was POI; secondary gastrointestinal recovery outcomes were: time to first flatus, time to first bowel movement, time to tolerating a liquid diet, time to tolerating solid food, and LOS. RESULTS: When compared with the control group, patients in the alvimopan group had shorter times to tolerating liquids and solids, first flatus, and first bowel movements (p < 0.01). LOS was shorter in the alvimopan group when compared with controls (p < 0.01). The overall incidence of POI was higher in controls than in the alvimopan group (p = 0.07). For laparoscopic surgeries, the incidence of POI was also higher in controls than in the alvimopan group (p < 0.01). On multivariable analysis, alvimopan significantly decreased time to all gastrointestinal recovery endpoints when compared to controls (p < 0.01). CONCLUSIONS: Alvimopan is effective in accelerating time to gastrointestinal recovery and reducing POI in IBD patients. While the benefits of alvimopan have been demonstrated previously, this is the first study of the efficacy of alvimopan in IBD patients.